Danish diabetes care giant Novo Nordisk (NOV: N) plans to invest an estimated $2 billion over the next five years in new production facilities in Clayton, North Carolina, USA, and in Måløv, Denmark.
The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines. The investment is estimated to create close to 700 new production and engineering jobs in Clayton where Novo Nordisk already employs more than 700people.
Novo Nordisk also plans to establish a new production facility in Måløv, Denmark for tableting and packaging of oral semaglutide and future oral products. The investment in Måløv will create an estimated 100 new jobs.
To initiate Ph IIIa development of oral semaglutide
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze